US court upholds Eisai’s Lenvima patent, blocking Shilpa’s generic until 2036; key IP win in oncology portfolio.
Moderna’s H5 flu vaccine shows strong immune response in Phase 1/2; HHS ends late-stage funding, new paths explored.
Keros ends TROPOS trial of cibotercept in PAH after safety concerns; strategic review underway for future development.